Ryan Smith, MD
Ophthalmology · Upland, CANPI 1164809851
Payments from drug & device makers
Across 531 payments — averaging $277.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$43K
- Johnson & Johnson Surgical Vision, Inc.$41K
- Bausch & Lomb Americas Inc.$21K
- Glaukos Corporation$21K
- Rxsight Inc$4K
- Dompe US, Inc.$3K
- plus $15K from 29 others
What the payments were for
- Consulting fees$53,67136%
- Speaking & faculty fees$59,37840%
- Travel & lodging$11,4068%
- Food & beverage$23,03916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 54 | $42,526 |
| Johnson & Johnson Surgical Vision, Inc. | 113 | $41,346 |
| Bausch & Lomb Americas Inc. | 75 | $21,023 |
| Glaukos Corporation | 47 | $20,796 |
| Rxsight Inc | 20 | $3,585 |
| Dompe US, Inc. | 18 | $3,064 |
| Alcon Research LLC | 2 | $3,000 |
| Mallinckrodt Hospital Products Inc. | 19 | $1,969 |
| AbbVie(2 entities) | 16 | $1,738 |
| Sight Sciences, Inc. | 41 | $1,589 |
| Alcon | 37 | $1,475 |
| Lensar, Inc. | 3 | $1,056 |
| Tearlab Corp | 2 | $889 |
| Beaver-visitec International, Inc. | 2 | $613 |
| Harrow Eye, LLC | 12 | $407 |
| Kala Pharmaceuticals, Inc. | 9 | $320 |
| Biotissue Holdings Inc. | 8 | $315 |
| Carl Zeiss Meditec USA, Inc. | 5 | $299 |
| Sun Pharmaceutical Industries Inc. | 10 | $297 |
| Ivantis, Inc | 5 | $183 |
| Novartis | 4 | $166 |
| Aerie Pharmaceuticals, Inc. | 3 | $143 |
| Amgen(2 entities) | 5 | $108 |
| Merz Pharmaceuticals, LLC | 1 | $105 |
| Stryker | 1 | $81 |
| Nova Eye, Inc. | 1 | $72 |
| Thea Pharma Inc. | 3 | $58 |
| Oyster Point Pharma, Inc. | 3 | $56 |
| ANI Pharmaceuticals, Inc. | 3 | $52 |
| Carl Zeiss Meditec, Inc. | 2 | $42 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $37 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| NEW World Medical,inc. | 2 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$28,953
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$28,481
- Tecnis Simplicity$7,320
- iDose$5,759
- CE-marked KXLA system$5,691
- Travoprost Intraocular Implant - iDose$4,193
- STELLARIS ELITE$3,093
- RXSIGHT CONTACT LENS$2,775
- RXSIGHT INJECTOR CARTRIDGE$2,775
- RXSIGHT INJECTOR HANDPIECE$2,775
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,775
- LIGHT ADJUSTABLE LENS (LAL)$2,775
- Oxervate$2,698
- Tecnis IOL$2,105
- IC-8 Apthera IOL$1,965
- enVista MX60 IOL$1,965
- XIIDRA$1,693
- MIEBO$1,575
- ACTHAR$1,550
- IPRIME$1,500
How this compares
$147,494 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 115 | $147,567 |
| XdemvyLotilaner | 73 | $136,617 |
| RestasisCyclosporine | 81 | $64,510 |
| Cyclosporine | 135 | $61,808 |
| MieboPerfluorohexyloctane/Pf | 52 | $45,891 |
| Prednisolone Acetate | 660 | $27,092 |
| CequaCyclosporine | 12 | $17,675 |
| LumiganBimatoprost | 28 | $16,545 |
| RhopressaNetarsudil Mesylate | 18 | $8,096 |
| EliquisApixaban | 11 | $6,807 |
| Ofloxacin | 381 | $5,496 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $5,331 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $5,141 |
| IlevroNepafenac | 14 | $5,126 |
| VyzultaLatanoprostene Bunod | 11 | $4,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $21,023 | $198,311178 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $42,526 | $136,61773 claims |
| AbbVieRestasis, Lumigan | $1,738 | $81,055109 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $297 | $17,67512 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $143 | $13,23731 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $37 | $6,56827 claims |
| AlconSimbrinza | $1,475 | $5,33126 claims |
| NovartisIlevro | $166 | $5,12614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Upland
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.